Cerevel Therapeutics Holdings, Inc.

NasdaqCM:CERE Stock Report

Market Cap: US$7.7b

Cerevel Therapeutics Holdings Valuation

Is CERE undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CERE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CERE ($42.38) is trading below our estimate of fair value ($132.38)

Significantly Below Fair Value: CERE is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CERE?

Other financial metrics that can be useful for relative valuation.

CERE key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-15.8x
PEG Ration/a

Price to Book Ratio vs Peers

How does CERE's PB Ratio compare to its peers?

The above table shows the PB ratio for CERE vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average9.2x
VKTX Viking Therapeutics
26.2x0.3%US$9.1b
PCVX Vaxcyte
6x-1.0%US$7.4b
EXEL Exelixis
3.2x23.3%US$7.2b
ROIV Roivant Sciences
1.4x-65.9%US$8.7b
CERE Cerevel Therapeutics Holdings
11.4x12.5%US$7.7b

Price-To-Book vs Peers: CERE is expensive based on its Price-To-Book Ratio (11.4x) compared to the peer average (9.2x).


Price to Earnings Ratio vs Industry

How does CERE's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.6%
n/an/an/a
No. of CompaniesPB048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a20.6%
n/an/an/a
No more companies

Price-To-Book vs Industry: CERE is expensive based on its Price-To-Book Ratio (11.4x) compared to the US Biotechs industry average (2.3x).


Price to Book Ratio vs Fair Ratio

What is CERE's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CERE PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio11.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CERE's Price-To-Book Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CERE forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$42.38
US$44.78
+5.7%
1.4%US$45.00US$43.00n/a9
Mar ’25US$41.05
US$44.78
+9.1%
1.4%US$45.00US$43.00n/a9
Feb ’25US$41.81
US$42.56
+1.8%
14.7%US$45.00US$25.00n/a9
Jan ’25US$42.40
US$42.56
+0.4%
14.7%US$45.00US$25.00n/a9
Dec ’24US$26.00
US$33.36
+28.3%
19.5%US$42.00US$24.00n/a11
Nov ’24US$25.35
US$33.56
+32.4%
18.6%US$42.00US$24.00n/a9
Oct ’24US$21.83
US$34.00
+55.7%
19.6%US$42.00US$24.00n/a9
Sep ’24US$23.66
US$34.13
+44.2%
20.7%US$42.00US$24.00n/a8
Aug ’24US$30.65
US$37.13
+21.1%
23.3%US$46.00US$22.00n/a8
Jul ’24US$31.79
US$37.13
+16.8%
23.3%US$46.00US$22.00n/a8
Jun ’24US$32.55
US$35.60
+9.4%
23.3%US$46.00US$22.00n/a10
May ’24US$31.30
US$35.90
+14.7%
26.6%US$52.00US$22.00n/a10
Apr ’24US$24.39
US$36.09
+48.0%
25.3%US$52.00US$22.00n/a11
Mar ’24US$27.64
US$38.80
+40.4%
19.5%US$52.00US$28.00US$41.0510
Feb ’24US$34.84
US$40.90
+17.4%
19.4%US$52.00US$28.00US$41.8110
Jan ’24US$31.54
US$40.82
+29.4%
18.5%US$52.00US$28.00US$42.4011
Dec ’23US$28.37
US$41.18
+45.2%
18.9%US$52.00US$28.00US$26.0011
Nov ’23US$29.32
US$41.73
+42.3%
17.8%US$52.00US$28.00US$25.3511
Oct ’23US$28.26
US$42.44
+50.2%
19.8%US$54.00US$28.00US$21.839
Sep ’23US$29.80
US$42.71
+43.3%
24.2%US$54.00US$24.00US$23.667
Aug ’23US$27.66
US$40.29
+45.6%
23.7%US$50.00US$24.00US$30.657
Jul ’23US$26.42
US$41.33
+56.4%
25.6%US$50.00US$20.00US$31.796
Jun ’23US$26.41
US$41.71
+57.9%
23.6%US$50.00US$20.00US$32.557
May ’23US$29.28
US$44.71
+52.7%
17.4%US$50.00US$28.00US$31.307
Apr ’23US$37.15
US$45.00
+21.1%
16.0%US$50.00US$30.00US$24.397
Mar ’23US$28.37
US$44.83
+58.0%
17.3%US$50.00US$30.00US$27.646

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.